Skip to content

Manipulative and Massage Therapy in the Lower Thoracic and Cervical Spine in Subjects With Fibromyalgia Syndrome

Effects of Manipulative Therapy in the Lower Thoracic and Cervical Spine in Subjects With Fibromyalgia Syndrome

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02864524
Enrollment
64
Registered
2016-08-12
Start date
2016-08-31
Completion date
2021-06-30
Last updated
2020-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Keywords

Physical Therapy Modalities, Exercises, Musculoskeletal Manipulations

Brief summary

Objective: Compare degree of improvement can reach patients diagnosed with fibromyalgia syndrome, by treatment with Manipulative and Massage Techniques versus an exercise program for lower thoracic and cervical spine. Study Design: A single-blind randomized controlled trial was conducted on patients with fibromyalgia syndrome (FMS). Setting: Clinical setting. Methods: Sixty-four subjects with FMS were randomly assigned to an experimental group receiving manipulative and massage therapy, or to a control group for exercise program.

Interventions

OTHERManipulative and Massage Therapy
OTHERExercise Program

Sponsors

Universidad de Almeria
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed Fibromyalgia Syndrome. * Limitation of usual activities due to pain on at least 1 day in the previous 30 days. * Agreement to attend evening therapy sessions. * Non-practice of regular physical activity.

Exclusion criteria

* A history of surgery. * The presence of comorbid conditions (e.g., morbid obesity, inflammatory diseases, irritable bowel syndrome and interstitial cystitis). * A history of whiplash injury. * Severe physical disability. * Uncontrolled endocrine disorders (e.g., hyperthyroidism, diabetes). * Illness (e.g., schizophrenia or substance abuse). * The use of medication other than as-needed analgesics (excluding long-term narcotics). * Malignancy. * Psychiatric disorders. * A score of ≥ 9 points in the Beck depression inventory.

Design outcomes

Primary

MeasureTime frameDescription
Pain IntensityChanges from Baseline, and 5 weeksA 10-point numerical scale (0 = no pain, 10: very severe pain)

Secondary

MeasureTime frame
Pittsburgh Quality of Life QuestionnaireChanges from Baseline, and 5 weeks
Quality of Life Questionnaire (SF-36)Changes from Baseline, and 5 weeks
Fibromyalgia Impact Questionnaire (FIQ)Changes from Baseline, and 5 weeks
Hospital Anxiety and Depression Scale (HADS)Changes from Baseline, and 5 weeks
McGill Pain QuestionnaireChanges from Baseline, and 5 weeks
Fatigue Impact Scale (FIS)Changes from Baseline, and 5 weeks
Schöber TestChanges from Baseline, and 5 weeks
Pressure AlgometryChanges from Baseline, and 5 weeks
Beck Depression InventoryChanges from Baseline, and 5 weeks

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026